Abliva AB (publ) (NEVPF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -93.6 Million SEK | -9.85% |
| 2022 | -79.89 Million USD | 40.71% |
| 2021 | -120.86 Million USD | -84.0% |
| 2020 | -58.09 Million USD | 15.35% |
| 2019 | -74.62 Million USD | -4.88% |
| 2018 | -68.12 Million SEK | -12.97% |
| 2017 | -69.86 Million SEK | -32.0% |
| 2016 | -70.64 Million SEK | 25.49% |
| 2015 | -89.54 Million SEK | 83.28% |
| 2014 | -43.68 Million SEK | -100.62% |
| 2013 | -21.77 Million SEK | -33.02% |
| 2012 | -16.37 Million SEK | -76.51% |
| 2011 | -9.27 Million SEK | -126.18% |
| 2010 | -4.1 Million SEK | -178.95% |
| 2009 | -1.47 Million SEK | 5.7% |
| 2008 | -1.55 Million SEK | -27.73% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.34 Million USD | -42.77% |
| 2024 Q1 | -1.73 Million USD | 28.59% |
| 2023 FY | - USD | -9.85% |
| 2023 Q2 | -2.14 Million USD | -35.34% |
| 2023 Q3 | -2.13 Million USD | 0.56% |
| 2023 Q4 | -2.38 Million USD | -11.7% |
| 2023 Q1 | -1.58 Million USD | 10.74% |
| 2022 Q2 | -1.69 Million SEK | 23.39% |
| 2022 Q3 | -2.28 Million USD | -35.14% |
| 2022 Q4 | -1.77 Million USD | 22.2% |
| 2022 FY | - USD | 40.71% |
| 2022 Q1 | -2.2 Million SEK | 44.6% |
| 2021 Q3 | -3.86 Million SEK | -11.84% |
| 2021 Q4 | -3.98 Million SEK | -3.03% |
| 2021 Q1 | -2.36 Million SEK | 81.02% |
| 2021 Q2 | -3.45 Million SEK | -46.49% |
| 2021 FY | - USD | -84.0% |
| 2020 Q3 | -9.41 Million SEK | 52.11% |
| 2020 Q4 | -12.44 Million SEK | -32.14% |
| 2020 FY | - USD | 15.35% |
| 2020 Q1 | -15.9 Million SEK | 39.74% |
| 2020 Q2 | -19.66 Million SEK | -23.68% |
| 2019 Q2 | -20.17 Million SEK | -52.37% |
| 2019 FY | - USD | -4.88% |
| 2019 Q1 | -13.24 Million SEK | 20.48% |
| 2019 Q3 | -14.67 Million SEK | 27.27% |
| 2019 Q4 | -26.39 Million SEK | -79.84% |
| 2018 Q1 | -12.52 Million SEK | 16.65% |
| 2018 Q2 | -24.46 Million SEK | -95.38% |
| 2018 Q3 | -14.48 Million SEK | 40.8% |
| 2018 Q4 | -16.65 Million SEK | -14.98% |
| 2018 FY | - SEK | -12.97% |
| 2017 Q4 | -15.02 Million SEK | -21.45% |
| 2017 Q3 | -12.37 Million SEK | 42.55% |
| 2017 Q2 | -21.53 Million SEK | -2.57% |
| 2017 Q1 | -20.99 Million SEK | -45.94% |
| 2017 FY | - SEK | -32.0% |
| 2016 Q2 | -11.76 Million SEK | -10.88% |
| 2016 Q1 | -10.6 Million SEK | -58.41% |
| 2016 Q3 | -33.89 Million SEK | -188.12% |
| 2016 FY | - SEK | 25.49% |
| 2016 Q4 | -14.38 Million SEK | 57.56% |
| 2015 Q1 | -14.05 Million SEK | 16.64% |
| 2015 Q3 | -53.41 Million SEK | -256.23% |
| 2015 Q4 | -6.69 Million SEK | 87.46% |
| 2015 Q2 | -14.99 Million SEK | -6.67% |
| 2015 FY | - SEK | 83.28% |
| 2014 Q4 | -16.86 Million SEK | -384.96% |
| 2014 FY | - SEK | -100.62% |
| 2014 Q1 | -9.75 Million SEK | -2.49% |
| 2014 Q2 | -13.59 Million SEK | -39.43% |
| 2014 Q3 | -3.47 Million SEK | 74.43% |
| 2013 Q1 | -4.68 Million SEK | 17.7% |
| 2013 FY | - SEK | -33.02% |
| 2013 Q4 | -9.51 Million SEK | -44.54% |
| 2013 Q3 | -6.58 Million SEK | -365.89% |
| 2013 Q2 | -1.41 Million SEK | 69.86% |
| 2012 Q2 | -4.1 Million SEK | -45.02% |
| 2012 Q1 | -2.83 Million SEK | -12.04% |
| 2012 FY | - SEK | -76.51% |
| 2012 Q4 | -5.69 Million SEK | -37.82% |
| 2012 Q3 | -4.13 Million SEK | -0.71% |
| 2011 Q4 | -2.52 Million SEK | -4.5% |
| 2011 FY | - SEK | -126.18% |
| 2011 Q2 | -3.13 Million SEK | -113.7% |
| 2011 Q1 | -1.46 Million SEK | -11.36% |
| 2011 Q3 | -2.41 Million SEK | 22.9% |
| 2010 Q1 | -520.29 Thousand SEK | -9.74% |
| 2010 FY | - SEK | -178.95% |
| 2010 Q3 | -1.43 Million SEK | -73.91% |
| 2010 Q2 | -826.2 Thousand SEK | -58.8% |
| 2010 Q4 | -1.31 Million SEK | 8.32% |
| 2009 FY | - SEK | 5.7% |
| 2009 Q2 | -401.74 Thousand SEK | -18.12% |
| 2009 Q1 | -340.1 Thousand SEK | 0.0% |
| 2009 Q3 | -294.12 Thousand SEK | 26.79% |
| 2009 Q4 | -474.12 Thousand SEK | -61.2% |
| 2008 FY | - SEK | -27.73% |
| 2007 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | -2956.073% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -2539.077% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -3997.547% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -438.906% |
| GB Sciences, Inc. | -1.41 Million USD | -6492.647% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 24808.851% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -765359.154% |
| Skye Bioscience, Inc. | -13.54 Million USD | -590.959% |
| Zenith Capital Corp. | -8.6 Million USD | -987.706% |
| Agentix Corp. | -1.37 Million USD | -6723.954% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -2309.894% |
| Biomind Labs Inc. | -1.03 Million USD | -8948.194% |
| ContraFect Corporation | -64.99 Million USD | -44.015% |
| CSL Limited | 4.78 Billion USD | 101.955% |
| CytoDyn Inc. | -18.02 Million USD | -419.208% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1392247.531% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -14701.884% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -69.154% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -25390.917% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5994.076% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -9890.725% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 199.543% |
| SQZ Biotechnologies Company | -64.14 Million USD | -45.941% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -6193.347% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -31.775% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -3439.794% |
| Mesoblast Limited | -62.38 Million USD | -50.037% |
| Marizyme, Inc. | -34.28 Million USD | -173.057% |
| Genus plc | 73.7 Million USD | 227.012% |
| Pharming Group N.V. | 9.87 Million USD | 1047.737% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -967.123% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6577.662% |
| IMV Inc. | -35.52 Million USD | -163.511% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -3928.195% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -17969.438% |
| ONE Bio Corp. | 13.61 Million USD | 787.635% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -94.099% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 2720.605% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -3136.426% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1207.142% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -374332.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -489.852% |
| Alpha Cognition Inc. | -9.7 Million USD | -864.474% |
| Enzolytics Inc. | -2.12 Million USD | -4311.25% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 56.668% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 7791.701% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1157.263% |
| Genscript Biotech Corporation | -248.71 Million USD | 62.364% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -1478.84% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -39041.961% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -3726.262% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -53079.003% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -4773.104% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1315.832% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1968.139% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -2398.599% |
| Helix BioMedix, Inc. | -1.04 Million USD | -8846.471% |
| EV Biologics, Inc. | -1.26 Million USD | -7287.391% |
| Q BioMed Inc. | -617.62 Thousand USD | -15056.049% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -5249.032% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -136.164% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1139.243% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -3641.384% |
| HST Global, Inc. | -5303.00 USD | -1765089.515% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -4450.705% |
| Halberd Corporation | -74.27 Thousand USD | -125922.16% |
| Resverlogix Corp. | -11.74 Million USD | -697.207% |
| Cell Source, Inc. | -4.27 Million USD | -2090.929% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -6145.088% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -1431.383% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -537228.512% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -8946.025% |
| Kadimastem Ltd | -2.62 Million USD | -3466.86% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -24558.343% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -51591.995% |
| LadRx Corporation | 412.28 Thousand USD | 22804.793% |
| Regen BioPharma, Inc. | 1.46 Million USD | 6485.458% |
| Affymax, Inc. | -14.29 Million USD | -554.83% |
| Itoco Inc. | -1.86 Million USD | -4908.467% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -8287.814% |
| Mobile Lads Corp. | -2.24 Million USD | -4076.767% |
| International Stem Cell Corporation | 202 Thousand USD | 46440.594% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -2350.377% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -118347.658% |
| Qrons Inc. | -40.08 Thousand USD | -233447.067% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -19173.675% |
| SYBLEU INC | -141.57 Thousand USD | -66020.886% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 17847.847% |
| Rebus Holdings, Inc. | -951 Thousand USD | -9743.113% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -8714.23% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -177726.748% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -3702.217% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -160.972% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -207917.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -3318.846% |
| Neutra Corp. | -181.24 Thousand USD | -51546.648% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -364.348% |
| PureTech Health plc | -11.62 Million USD | -705.092% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -364.38% |
| IXICO plc | -707 Thousand USD | -13140.17% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1118.061% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -93.621% |
| CSL Limited | 4.73 Billion USD | 101.978% |
| Cellectis S.A. | -92.63 Million USD | -1.049% |